GlassScriptPhysician profile
Rebecca E Jones
NPI 1952991200
$602.16
in general payments reported to CMS, 2019-2025
17 companies · $54.40 in 2025
The $54.40 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.36 · 2022: $147 · 2023: $214 · 2024: $173 · 2025: $54.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.46 | 2022-2024 | |
| Averitas Pharma INC. | $75.96 | 2023 | Qutenza |
| Boston Scientific Corporation | $50.30 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $45.26 | 2023-2024 | Breztri |
| Collegium Pharmaceutical, INC. | $41.69 | 2022-2023 | Belbuca |
| Phathom Pharmaceuticals, INC. | $34.36 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.50 | 2023 | Relistor |
| Astellas Pharma US INC | $31.59 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $28.19 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $28.15 | 2023-2024 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $27.85 | 2022 | |
| Spr Therapeutics, INC | $23.54 | 2022 | |
| Philips North America LLC | $22.81 | 2025 | Coronary Other |
| Glaxosmithkline, LLC. | $17.69 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Grt US Holding, INC. | $17.62 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.14 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $15.05 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.